Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biopharmaceutical company focused on oncolytic virotherapy, developing engineered stem-cell platforms designed to deliver cancer-killing viruses to tumor sites. The company reached the public markets through a SPAC merger with FLAG Health Sciences Acquisition Corp, which completed its IPO in 2021 and operated in the healthcare and life sciences sector. The January 2023 Form 8-K filing, bearing accession number 0001193125-23-004705, reflects activity during the de-SPAC process ahead of the merger's closing later in 2023. CLDI trades on Nasdaq following completion of the business combination. For the full filing history, sponsor details, and deal timeline for CLDI and thousands of other SPAC transactions, sign up for complete data access at SpacDesk.